The $6.0M offering provides near-term cash runway but at significant dilution given the $0.55 unit price. Monitor for potential warrant exercise over the next 5 years and any share combination event that could trigger price adjustments. The company's ability to achieve positive operating cash flow from its 61 generic drugs in Canada will determine whether further dilutive financing is needed.
Price Chart
Executive Summary
Sunshine Biopharma closed a best-efforts public offering raising approximately $6.0 million in gross proceeds via 10,909,082 units (common or pre-funded) plus Series D warrants exercisable at $0.66 per share. The offering is dilutive to existing shareholders and the warrants, if fully exercised on a cash basis, could add up to ~$14.4 million in additional proceeds. The company expects to use net proceeds for general corporate purposes and working capital.
Key Financial Metrics
Key Facts
- Closed best-efforts public offering of 10,909,082 units at $0.55 per common unit / $0.54999 per pre-funded unit
- Gross proceeds of approximately $6.0 million raised upfront
- Each unit includes either one share of common stock or one pre-funded warrant, plus two Series D warrants
- Series D warrants have an initial exercise price of $0.66 (120% of offering price), expire in 5 years, and are subject to price adjustment on share combination events with a floor of $0.275
- Pre-funded warrants were exercised in full prior to closing at $0.00001 per share
- Placement agent Aegis Capital Corp. received 7% fee plus 1% non-accountable expense allowance
- Potential additional gross proceeds of ~$14.4 million if Series D warrants are fully exercised on a cash basis
- Registration statement on Form S-1 (No. 333-299274) declared effective October 7, 2026
Financial Impact
$6.0 million raised upfront; up to ~$14.4 million additional if warrants exercised; 7% placement fee + 1% expense allowance
Risk Factors
- Substantial dilution to existing shareholders from issuance of 10.9M+ shares and up to 21.8M warrant shares
- Warrant overhang of up to ~21.8M shares exercisable at $0.66 could pressure stock price
- No assurance warrants will be exercised; potential additional proceeds are contingent
- Company is pre-revenue on proprietary drug pipeline (K1.1 mRNA, PLpro inhibitor) with no near-term commercialization
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007758 |
| Document: sunshine_ex1003.htm | 0001683168-26-007758 |
| Document: sunshine_ex1002.htm | 0001683168-26-007758 |
| Document: sunshine_8k.htm | 0001683168-26-007758 |
| Document: sunshine_ex9902.htm | 0001683168-26-007758 |
| Document: sunshine_ex9901.htm | 0001683168-26-007758 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | — |
Oct 13, 2026 12d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | — |
Oct 9, 2026 16d ago | 8-K | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | — |
Oct 9, 2026 16d ago | 424B4 | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | — |
Oct 8, 2026 18d ago | EFFECT | $0.4300 $0.2300 | ▲ +46.51% | ▲ +46.24% | — |
Oct 5, 2026 20d ago | SC 13G/A | $0.3979 $0.2363 | ▲ +40.61% | ▲ +40.47% | — |
Oct 2, 2026 23d ago | S-1 | $0.4201 $0.3020 | ▲ +28.11% | ▲ +28.53% | — |
Sep 9, 2026 6w ago | EFFECT | $1.12 $1.04 | ▲ +7.59% | ▲ +7.26% | — |
Aug 28, 2026 8w ago | 8-K | $1.12 $1.15 | ▲ +2.68% | ▲ +2.82% | — |
Aug 3, 2026 12w ago | 8-K | $1.17 $1.22 | ▲ +4.27% | ▲ +2.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers